Format

Send to

Choose Destination
Thromb Res. 2015 Jul;136(1):7-12. doi: 10.1016/j.thromres.2015.05.001. Epub 2015 May 8.

Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review.

Author information

1
Colorado Coagulation, Laboratory Corporation of America® Holdings, Englewood, CO, United States. Electronic address: adcockd@labcorp.com.
2
University of California, Davis Health System, Sacramento, United States.

Abstract

Direct oral anticoagulant therapies, including direct anti-Xa and thrombin inhibitors have recently been introduced and may have advantages over vitamin K antagonists such as warfarin. This review describes briefly the clinical utility and mechanism of action of these agents. Detailed information is provided on effect of these agents on routine assays including the APTT and PT as well as their impact on specialty laboratory assays. Also included are the use of drug specific assays and a discussion of alternative methods to determine relative drug concentration, such as evaluating drug calibrators in APTT and PT assays and using heparin calibrated anti-Xa assays to measure direct Xa inhibitors.

KEYWORDS:

DOAC; Direct Xa inhibitor; Direct thrombin inhibitor; Laboratory assays; Oral anticoagulant

PMID:
25981138
DOI:
10.1016/j.thromres.2015.05.001
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center